Friday, April 24, 2020

Gilead disputes report that its coronavirus drug failed in China trial

Gilead disputes report that its coronavirus drug failed in China trial
Barb~Gilead is the company that paid $247,000 for nonclinical research at VA on elderly, mainly black vets with comorbidities to show that hydroxycholoquine "killed" people, while pushing a competing drug.

No comments:

Post a Comment